Charles River Laboratories International : at the William Blair 45th Annual Growth Stock Conference Presentation

Published: 2025-06-03 08:15:05 ET CRL

Published on 06/03/2025 at 08:15

June 3, 2025

Flavia Pease

Executive Vice President & Chief Financial Officer

Working with clients from discovery and early-stage development through the safe manufacture of life-saving therapies

Leading, Global, Non-Clinical Drug Development Partner with a Mission to Create Healthier Lives

Global Scale

~20,000

Global employees

~2,500

Scientific professionals

with advanced degrees

>2,000

Biopharma clients (NA/EU)

~70%

Revenue from

biopharma industry

>130*

Locations in

>20

Countries

Attractive Market Position

Position in Research Models,

Safety Assessment & Microbial Solutions

Supported

>80%

of FDA-approved novel drugs over last five years (2020-24)

~$25B

addressable market opportunity provides long runaway for future growth

* Includes certain sites being consolidated as part of Company's footprint rationalization efforts.

** Other client segment includes agricultural & industrial chemical, CRO, animal health, life science, CDMO, consumer product, and

medical device companies.

Diverse Revenue Base by Region

27%

$4.0B

FY 2024 revenue

67%

North America

Europe

ROW

Balanced Revenue by

Client Segment**

15%-

20%

Largest client

~10%

<4%

FY 2024 revenue

40%-

45%

~30%

Biotech Academic/Gov't

Globals Other

Ensuring the quality and safety of manufacturing activities and commercial therapies

Manufacturing

Solutions

Full-service process development, clinical-to-commercial manufacturing, and quality-control testing products and services

Enabling preclinical success and efficiently advancing ideas into the clinic

Discovery and Safety

Assessment (DSA)

Largest, global partner for outsourced drug discovery, non-clinical development, and regulated safety testing services

Foundational tools that enable

clients to discover new molecules

Research Models and

Services (RMS)

Global leader in the production of the most widely used small research models and associated services

Basic

Research

Drug

Discovery

Non-Clinical

Development

Clinical

Development

Market

Approval

Commercial

Manufacture

Research & Development Continuum

Note: DSA segment provides certain services to support clinical development, including clinical bioanalysis/lab sciences. However, the Company does not conduct human clinical trials.

Disclaimer

Charles River Laboratories International Inc. published this content on June 03, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 03, 2025 at 12:14 UTC.